Clearside Biomedical

CLSD

Current ValuationThe current P/E ratio is -0.08, within the reasonable range, cheaper than 28.77% of the time in the past 3 years, and the industry ranks 67/255, the industry Median -1.26.

-0.0825xP/E
Stock price--

Historical Valuation

P/E ratioTypical rangeMedian

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
0295887116

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
P/E ratio
Name/Symbol
TAKUSTakeda Pharmaceutical Company
-56.67x148.12%$59.17B
BAYRYUSBayer
-23.84x--$48.10B
BAYZFUSBayer Aktiengesellschaft
-23.89x--$48.20B
VTRSUSViatris
-49.33x107.68%$20.26B
ELANUSElanco Animal Health
-57.54x129.36%$11.45B
VREOFUSVIREO GROWTH INC
-132.75x--$8.91B
AXSMUSAxsome Therap
-46.01x25.55%$8.82B
CURLFUSCuraleaf Holdings, Inc.
-138.15x--$7.19B
BLTEUSBelite Bio
-60.78x29.87%$6.22B
MANEUSVeraDermics
-52.44x97.44%$5.47B
DFTXUSDefinium Therapeutics
-14.01x54.37%$4.96B
EWTXUSEdgewise Therapeutics
-21.51x137.29%$4.24B
RGCUSRegencell Bioscience
-311.21x--$3.64B
AMLXUSAmylyx Pharmaceuticals
-23.22x1.76%$3.53B
TARSUSTarsus Pharmaceuticals
-69.08x205.82%$3.21B
ELVNUSEnliven Therapeutics
-28.35x6.39%$3.00B
MBXUSMBX Biosciences
-24.59x31.12%$2.56B
SUPNUSSupernus Pharma
-22.57x70.59%$2.48B
BHCUSBausch Health
-2.06x305.55%$2.26B
PHVSUSPharvaris BV
-11.00x10.73%$2.18B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.